



## PRESS RELEASE

Published 25-11-2020

### Asarina Pharma AB (publ) Q3 2020 report released

**Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa Menstrual Migraine study—despite tough Covid-19 restrictions, and continued preparations for our Phase IIa study in Tourette syndrome. We remain confident of completing both studies on schedule, so realizing our vision of bringing a new treatment modality to market for under-treated conditions that can help millions remain in control of their lives.”**

#### FINANCIAL HIGHLIGHTS

- R&D costs at same level as in Q2, 2020
- Reduction in G&A and staff costs after reorganisation
- Cash position on 30 September 2020: SEK 65 million

#### R&D HIGHLIGHTS

- **Completed enrolment for Phase IIa study in Menstrual Migraine** in Finland and Sweden. We are on schedule to publish topline results in June 2021.
- **Continued completing non-clinical studies in preparation for Phase IIa study in Tourette syndrome.** On schedule to submit a CTA to the Danish Regulatory Authorities before the end of February for approval, initiating study in June 2021.
- **Fully implemented internal reorganization.** We have adjusted our resources to the current project portfolio, and remain committed to completing the two Phase II studies in Menstrual Migraine and Tourette without raising additional funds.
- **Developed new saliva analysis test for presence of ALLO.** This quarter we have taken an important step towards being able to test for the presence of ALLO in neurological conditions using a simple, well-trusted diagnostic technique.

**For further information, please contact:**  
Peter Nordkild, CEO

Phone: +45 25 47 16 46

E-mail: [peter.nordkild@asarinapharma.com](mailto:peter.nordkild@asarinapharma.com)

Jakob Dynnes Hansen, CFO

Phone: +45 5132 3698

E-mail: [jakob.dynnes@asarinapharma.com](mailto:jakob.dynnes@asarinapharma.com)

### **Certified Adviser**

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### **About Asarina Pharma**

We are a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSAs compounds (GABA<sub>A</sub> Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

***The information above was provided by the CEO of Asarina Pharma AB (publ), for publication on November 25, 08.00, 2020.***